Skip to main content

Premaitha management changes add robustness

Premaitha management changes add robustness

Manchester-based Premaitha Health, the developer of a ground-breaking non-invasive prenatal test (NIPT) for Down’s Syndrome in unborn children, has announced a raft of management changes as the commercialisation of its IONA test begins to gather pace.

Chief medical officer Dr William Denman is to join the board of the AIM-listed company after being with the company for more than four year years. Meanwhile, the remit of Peter Collins will be broadened to take on the role of chief business officer.

Chairman David Evans said: “We look forward to the coming year, in which we will continue to prioritise the commercialisation of our test and product development. We intend to further develop our business through closer collaboration with key opinion leaders, our platform and distribution partners.”

The management reshuffle coincides with news that Premaitha and the Wolfson Institute – part of St Bart’s and the London School of Medicine and Dentistry and Britain’s leading research and service facility for antenatal screening for Down’s – are collaborating in a world first for NIPT, using the IONA test.

See article in full at TheBusinessDesk.com